In women with hypoactive sexual desire disorder, pooled medication trials (testosterone, flibanserin and bremelanotide) had a mean Cohen d effect size of 1.0 (SD 0.34), similar to CBT and MMT at 1.0.
In plain wordsIn women with low sexual desire, several drugs pooled together showed a large effect, similar to talking therapies. Not a bremelanotide-only result.
- Peptide
- Bremelanotide (PT-141)
- Outcome
- Not applicableEffect size of medications on sexual desire and distress
- Study
n: not reported in source
- Comparator
- Placebo and wait list
- Outcome group
- Sexual function · Reproductive and sexual health
Measurements
- Cohen d, medications
- 1 SD 0.34
- pooled medications
- Cohen d, CBT and MMT
- 1 SD 0.36
- psychotherapy
Source sentences
For medications, mean (SD) effect size was 1.0 (0.34); for CBT and MMT, 1.0 (0.36); for placebo, 0.55 (0.16); and for wait list, 0.05 (0.26).
2 context sentences(design, population, supporting numbers)
For efficacy trials of HSDD in women, compare effect sizes for medications (testosterone/testosterone transdermal system, flibanserin, and bremelanotide) and placebo vs effect sizes for psychotherapy and wait-list control.
We conducted a literature search for mean changes and SD on main measures of sexual desire and associated distress in trials of medications, CBT, or MMT.
In this study, Bremelanotide (PT-141) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bremelanotide (PT-141).